Gastro-oesophageal reflux disease

Medical Journal of Australia

Volumn 169, Issue 10, 1998, Pages 549-554

  De Carle, David J ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CASE REPORT; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; DYSPEPSIA; ENDOSCOPY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; INDIGESTION; LIFESTYLE; MALE; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PH MEASUREMENT; RECURRENT DISEASE; STOMACH FUNDOPLICATION;

EID: 0032539031     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1998.tb123409.x     Document Type: Article

References (30)

1. Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 433-445.
2. Talley NJ, Colin-Jones D, Koch KL, et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Intl 1991; 4: 145-160.
3. Jones R. Dyspeptic symptoms in the community. Gut 1989; 30: 893-838.
4. Jones RH, Lydeard SE, Hobbs FDR, et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401-405.
5. Castell DO. Introduction to pathophysiology of gastroesophageal reflux. In: Castell DO, Wu WC, Ott DJ, editors. Gastro-esophageal reflux disease: pathogenesis, diagnosis and therapy. New York: Futura Publishing, 1985: 3-9.
6. Nebel O, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-956.
7. Westbrook JI, Talley NJ, McIntosh JH. Dyspepsia prevalence, subgroups and health care seeking - random survey of 2300 households [abstract]. Gastroenterology 1998; 114: A49.
8. Johansson K, Ask P, Boeryd B, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986; 21: 837-847.
9. Barbezat GO. Reflux oesophagitis. Br J Hosp Med 1995; 54: 583-586.
10. Ryan P, Hetzel DJ, Shearman DJ, McMichael AJ. Risk factors for ulcerative reflux oesophagitis: a case-control study. J Gastroenterol Hepatol 1995; 306-312.
11. Johnsson F, Joelsson B, lsberg P-E. Ambulatory 24-hour pH monitoring in the diagnosis of gastroesophageal reflux disease. Gut 1987; 28: 1145-1150.
12. Agreus L, Talley NJ. Natural history of reflux, dyspepsia and irritable bowel over 7 years in the general population. Gastroenterology 1998; 114: A2.
13. Hetzel D, Dent J, Reed W, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-912.
14. Nanduker S, Talley NJ, Martin CJ, et al. Short segment Barrett's oesophagus prevalence, diagnosis and associations. Gut 1997; 40: 710-715.
15. Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective three-year follow-up. Am J Gastroenterol 1997; 92: 2012-2015.
16. Isolauri J, Lüostarinen M, lsolauri E, et al. Natural course of gastroesophageal reflux disease: a 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41.
17. Kuster E, Ros E, Toledo-Pimental V, et al. Predictive factors of the long-term outcome in gastro-oesophageal reflux disease: six-year follow-up of 107 patients. Gut 1994; 35: 8-14.
18. Klauser AG, Schindlebeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205-208.
19. Jacob P, Kahrilas P, Herzon G. Proximal esophageal pH-metry in patients with "reflux laryngitis". Gastroenterology 1991; 100: 305-310.
20. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterology 1997; 32: 974-979.
21. Weinstein WM, Borgoch ER, Bowes KL. The normal human esophageal mucosa: a histological appraisal. Gastroenterology 1975; 68: 40-44.
22. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with non-cardiac chest pain. Gastroenterology 1998; 115: 42-49.
23. Australian Gastroenterology Institute. Gastro-oesophageal reflux disease in adults. 2nd ed. Sydney: AGI, 1996.
24. 2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 Suppl 1: 9-14.
25. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107: 1305-1311.
26. De Boer WA, Tytgat GN. Drug therapy for reflux oesophagitis. Aliment Pharmacol Ther 1994; 8: 147-157.
27. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-1810.
28. Sampliner RE. Effect of up to 3 years of high dose lansoprazole on Barrett's oesophagus. Am J Gastroenterology 1994; 89: 1844-1848.
29. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12.
30. Laine S, Rantala A, Gullichsen R. Laparoscopic vs conventional Nissen fundoplication. A prospective randomised study. Surg Endosc 1997; 11: 441-444.